Mehdi Koushki1, Nasrin Amiri Dashatan2, Reza Meshkani3. 1. Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, I.R Iran. 2. Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran. 3. Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, I.R Iran. Electronic address: rmeshkani@tums.ac.ir.
Abstract
PURPOSE: The evidence has suggested that resveratrol has anti-inflammatory effect; however, the results are inconsistent and inconclusive. The aim of this study was to assess the effect of resveratrol supplementation on the levels of inflammatory markers through a systematic review and meta-analysis of available randomized controlled trials (RCTs). METHODS: A search strategy was completed using Medline, ISI Web of Science, Directory of Open Access Journal, SID, ProQuest, Cochrane Library, Scopus, and EMBASE up to May 2017, to identify placebo-controlled RCTs that assessed resveratrol effects on circulating (serum and plasma) inflammatory markers (interleukin [IL]-6, tumor necrosis factor-α [TNF-α], and high-sensitivity C-reactive protein [hs-CRP]) among adult participants aged 17 years and older in 17 RCTs with a total of 736 subjects. The evaluation of study quality was performed using the Jadad scale. Weighted mean difference (WMD) was calculated for evaluating the changes in the inflammatory markers using fixed-effects or random-effects models. We performed subgroup and sensitivity analyses to evaluate the heterogeneity of the studies. FINDINGS: Seventeen RCTs, including 736 subjects, fulfilled the eligibility criteria and were selected for analyses. The results of meta-analysis found significant reductions in the level of TNF-α (WMD, -0.44; 95% CI, -0.71 to -0.164; P = 0.002; Q statistic = 21.60; I2 = 49.1%; P = 0.02) and hs-CRP (WMD, -0.27; 95% CI, -0.5 to -0.02; P = 0.033; Q statistic = 26.95; I2 = 51.8%; P = 0.013) after supplementation with resveratrol. Resveratrol supplementation had no significant effect on the level of IL-6 (WMD, -0.16; 95% CI, -0.53 to 0.20; P = 0.38; Q statistic = 36.0; I2 = 72.3%; P = 0.001). Statistically significant heterogeneity was observed for the type of sample in IL-6 and study duration in inflammatory markers IL-6, TNF-α, and hs-CRP. IMPLICATIONS: Available evidence from RCTs suggests that resveratrol supplementation significantly reduced TNF-α and hs-CRP levels. Significant improvement in inflammatory markers support resveratrol as an adjunct to pharmacologic management of metabolic diseases.
PURPOSE: The evidence has suggested that resveratrol has anti-inflammatory effect; however, the results are inconsistent and inconclusive. The aim of this study was to assess the effect of resveratrol supplementation on the levels of inflammatory markers through a systematic review and meta-analysis of available randomized controlled trials (RCTs). METHODS: A search strategy was completed using Medline, ISI Web of Science, Directory of Open Access Journal, SID, ProQuest, Cochrane Library, Scopus, and EMBASE up to May 2017, to identify placebo-controlled RCTs that assessed resveratrol effects on circulating (serum and plasma) inflammatory markers (interleukin [IL]-6, tumor necrosis factor-α [TNF-α], and high-sensitivity C-reactive protein [hs-CRP]) among adult participants aged 17 years and older in 17 RCTs with a total of 736 subjects. The evaluation of study quality was performed using the Jadad scale. Weighted mean difference (WMD) was calculated for evaluating the changes in the inflammatory markers using fixed-effects or random-effects models. We performed subgroup and sensitivity analyses to evaluate the heterogeneity of the studies. FINDINGS: Seventeen RCTs, including 736 subjects, fulfilled the eligibility criteria and were selected for analyses. The results of meta-analysis found significant reductions in the level of TNF-α (WMD, -0.44; 95% CI, -0.71 to -0.164; P = 0.002; Q statistic = 21.60; I2 = 49.1%; P = 0.02) and hs-CRP (WMD, -0.27; 95% CI, -0.5 to -0.02; P = 0.033; Q statistic = 26.95; I2 = 51.8%; P = 0.013) after supplementation with resveratrol. Resveratrol supplementation had no significant effect on the level of IL-6 (WMD, -0.16; 95% CI, -0.53 to 0.20; P = 0.38; Q statistic = 36.0; I2 = 72.3%; P = 0.001). Statistically significant heterogeneity was observed for the type of sample in IL-6 and study duration in inflammatory markers IL-6, TNF-α, and hs-CRP. IMPLICATIONS: Available evidence from RCTs suggests that resveratrol supplementation significantly reduced TNF-α and hs-CRP levels. Significant improvement in inflammatory markers support resveratrol as an adjunct to pharmacologic management of metabolic diseases.
Authors: Allan Saj Porcacchia; Gustavo Antonio Moreira; Monica Levy Andersen; Sergio Tufik Journal: J Clin Sleep Med Date: 2022-01-01 Impact factor: 4.062
Authors: Małgorzata Chudzińska; Daniel Rogowicz; Łukasz Wołowiec; Joanna Banach; Sławomir Sielski; Robert Bujak; Anna Sinkiewicz; Grzegorz Grześk Journal: Ir J Med Sci Date: 2020-11-21 Impact factor: 1.568
Authors: Andrea Deledda; Giuseppe Annunziata; Gian Carlo Tenore; Vanessa Palmas; Aldo Manzin; Fernanda Velluzzi Journal: Antioxidants (Basel) Date: 2021-04-29
Authors: Kathleen S Hodgin; Emily K Donovan; Sophia Kekes-Szabo; Joanne C Lin; Joseph Feick; Rebecca L Massey; Timothy J Ness; Jarred W Younger Journal: Int J Environ Res Public Health Date: 2021-03-03 Impact factor: 3.390